All In Biotech

Free tool

FAERS Monitor: Aspruzyo Sprinkle

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 216018 or its brand name (Aspruzyo Sprinkle, Ranolazine). Reports on generic versions are filed under their own applications.

Reports

10,544

Serious

9,584

91% of reports

Hospitalization

4,510

Death reported

1,344

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • death831
  • myocardial infarction650
  • chest pain622
  • angina pectoris599
  • stent placement582
  • dyspnoea447
  • dizziness438
  • fall387
  • cerebrovascular accident356
  • cardiac disorder311
  • off label use302
  • nausea292
  • malaise287
  • drug interaction284
  • fatigue277

Reports by year received

View as table
YearReports
20051
20062
20077
200815
200923
201033
201161
2012115
2013133
2014548
20151,488
20161,180
20171,382
20181,435
2019984
2020331
2021313
2022370
2023426
2024516
2025674
2026507

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,043,615 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
stent placementSignal582155.1142.882,561
angina pectorisSignal59942.639.323,796
myocardial infarctionSignal6507.56.93,644
chest painSignal6226.76.23,038
cardiac disorderSignal3116.66.01,489
cerebrovascular accidentSignal3564.23.8869
drug interactionSignal2843.63.2527
fallSignal3872.32.1294
death8311.91.8384
dizziness4381.81.6144
dyspnoea4471.61.496
malaise2871.31.221
nausea2920.70.728
fatigue2770.70.634
off label use3020.70.644

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.